

Status of Clinical Trial Environment in Thailand

by Yuppadee JAVROONGRIT, Ph.D.

Head of International Affairs and Investigational Drug Group Drug Control Division, TFDA, MOPH, <u>Thailand</u>

Preliminary workshop: Review of Drug Development in Clinical Trials
Pathumwan Princess Hotel, Bangkok, Thailand
17-21 March 2008



Outline:

- Sponsor & CRO
- Investigator
- Ethical Committee (EC)
- Regulation
- Others





Sponsor & CRO

- Current Sponsors (for 291 trials -as of 27 Aug 07)
 - major are MNCs (63%)
 - also others (University/Organization 25%, NIH 8%, and other Federal Agency 4%)

• CRO

- domestic CRO (Medica Innova,...)
- normal CRO (Apex, Covance, Quintites)
- Institute-CRO networking (Aclires, Apec-IATEC)

• Trend & Plan :-

- provide Training
- internal Auditing
- enhance Successful in competitive enrollment
- -imported Tax





Investigator

- experienced (in Pharmaceutical, and Biological Trials)
 - various Phases :- I, II, III, and IV
 - Vaccines
 - various area :-Cancer, Cardiovascular, D.M., Hepatitis, HIV/AIDs, Infectious & Topical diseases, Accidental Injury/Trauma)

Networking

- CRCN (Clinical Research Collaboration Network)
- HIV-NAT (The Thai Red Cross AIDS Research Center)

Trend & Plan :-

- to increase in a Numbers
- to improve Quality & Speed of the Trial
- to work in New highly technology (i.e. Snip,
- enhancing the contribution to the R&D





Ethical Committee

- Current ECs (~20 ECs)
 - Types:- government, academic, private
 - Joint Research Ethics Committee (JREC)
- Standards
 - International Std. (CIOMS, ICH-GCP, Declaration of Helsinki, WHO)
 - Strengthening Members (Training, and Study Visit-WIRB)
- Networking :-
 - FERCIT Forum of Ethical Review Committees in Thailand
 - FERCAP Forum of Ethical Review Committee in the Asian & Western Pacific Region
- Trend & Plan :-
 - SIDCER / FERCAP audit-recognition programme
 - OHRP/FWA Registration
 - acceptant by the TFDA
 - competitive Timeline





Regulation by TFDA

Current

- sequence Application, after EC Approval
- need :-
 - Drug label
 - Drug leaflet
 - CFS (or EC Approval)
 - Clinical Trial Report
 - Clinical Trial Protocol
- Requirement :-voluntary
 - GCP
 - Report of "Unexpected-SADR"
- Scientific Review/Assessment
 - partial & initiative step
- Accepted ECs
 - design by Sub-National Drug Committee
 - total of 9 ECs
- GCP Inspection :- N/A

New

- might allow "Parallel Application"
- need :-
 - Drug label
 - Drug leaflet (for registered Drug)
 - Investigator Brochure
 - Patient Information Sheet (in Thai)
 - Clinical Trial Protocol
 - Info. on Drug Quality & GMP
- Requirement :-mandatory
 - GCP
 - GMP
 - Report of "Unexpected-SADR"
- Scientific Review/Assessment
 - Systemic & Fully implement
- Accepted ECs
 - formal System
 - coop. with SIDCER/FERCAP
- GCP Inspection :- formal System
- IND→ NDA



Others

Infrastructure

- pop. ~ 65 mill.
- Med.Hospital Faculty =12
- Health Professional Resources;
 - ~ 29,000 Physician
 - ~ 8,000 Dentist
 - ~ 18,000 Pharmacist
 - ~ 153,000 Nurse

ICRCC

(International Clinical Research Collaboration Center)

- Members:
 - CRCN
 - PReMA
 - TCELS
 - TDRI
- Activites:
 - info. exchange
 - management team
 - research collaboration& services
 - Quality system
 - network to all Stakeholder
- Outcome:
 - Clinical Research Center

SIDCER

(The Strategic Initiative for Developing Capacity in Ethical Review)

- Primary Objective: to contribute to human subject protections globally by developing capacity in ethical review and the ethics of health research.
- Activites:
 - survey
 - training
- Cooperation with TFDA:
 - Acceptance EC's List
 - Capacity building

Situation

- GCP adopted in 2000
- ~ 6,000 trainees on GCP(y.2002-7)
- active and closely cooperation
- regular Annual Seminar
- willing & ready for participate "Global Drug Development"





Thank You มอบคุณคะ